Last $0.44 USD
Change Today +0.0059 / 1.37%
Volume 238.5K
KBIO On Other Exchanges
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

R. Andrew McMillan Ph.D.

AgeTotal Calculated CompensationThis person is connected to 31 board members in 3 different organizations across 6 different industries.

See Board Relationships


Dr. R. Andrew McMillan, Ph.D. serves as a Board Observer of Ambrx Inc., Antipodean Pharmaceuticals Inc., KaloBios Inc. and Pearl Therapeutics Inc. Dr. McMillan serves as a Director of Wildcat Discovery Technologies, Inc. He serves as a Board Observer of Achaogen Inc. Dr. McMillan was a Principal at 5AM Ventures since February 20, 2008. He joined 5AM Ventures in 2005 as a Senior Associate. Dr. McMillan was a Principal Investigator in the Bioengineering Branch of NASA. ...

Read Full Background

Corporate Headquarters*

260 East Grand Avenue
South San Francisco, California 94080

United States

Phone: 650-243-3100
Fax: --

Board Members Memberships*

Board Observer
Former Board Observer
Board Observer


University Of North Carolina At Chapel Hill
Emory University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KBIO:US $0.44 USD +0.0059


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALOBIOS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at